The opportunity
Opportunity to acquire a proven behavioural science platform business, combining proprietary resilience-based methodology with human-guided delivery.
Founded in 2020 and backed by public market investment, the business has developed a scalable technology platform that enables healthcare and pharma companies to improve clinical trial adherence and retention, increase returns on patient support programs and enhance treatment outcomes.
Rationale for sale
Restrictions on the availability of growth capital via the public markets means the business is looking for a new investor/partner to accelerate and scale the business.
Highlights
- Across pharma and healthcare, non-adherence and clinical trial drop-off drive an estimated $16bn–$24bn in annual value loss, which the business is designed to address
- The solution is operational and has now been commercialised through an initial launch with a Fortune 500 biotech, pharma, and MedTech customer
- Active deployments in phase 2 and 3 clinical trials, including with global pharmaceutical and biotechnology companies
- Achieved preferred vendor status with leading clinical research organisations
- Content licensing agreement with a top-tier US pharmaceutical company
- Library of 180+ tailored behavioural tools targeting adherence and trial participation
- US and Canadian Patents secured
- The business is now seeking private investment to scale, building on prior funding of over $30m
Financial overview
- Initial revenue of c.$500k following launch
- Strong commercial pipeline across pharma and healthcare customers
- Double digit growth forecast for FY26, with significant operating leverage as deployments scale
Interest & offers
- Expressions of interest are sought for the purchase of this US business
- Offers required by 12pm 24th April 2026
- Interested parties will be requested to sign a non-disclosure agreement (NDA)
- Potential purchaser will need to provide proof of funds and be able to transact in an accelerated timeframe
